Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma

Cecilia Simonelli, Stefania Zanussi, Roberta Cinelli, Luigino Dal Maso, Giampiero Di Gennaro, Monica D'Andrea, Guglielmo Nasti, Michele Spina, Emanuela Vaccher, Paolo De Paoli, Umberto Tirelli

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We evaluated the replication and resistance patterns of human immunodeficiency virus (HIV) strains recovered from HIV-infected patients with non-Hodgkin lymphoma (NHL) who were receiving chemotherapy (CT) concomitant with highly active antiretroviral therapy (HAART). We analyzed virological response to HAART in 35 patients with HIV and NHL who were treated with a cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy regimen and HAART and the virological response in 26 HIV-infected patients with CD20 cell-positive NHL who were treated with rituximab and cyclophosphamide-doxorubin-etoposide therapy. Genotype and virtual phenotype analyses were performed at baseline and when virological failure occurred. Only 9 patients met the criteria for virological failure. Genotype and virtual phenotype analyses demonstrated that, during CT administration, new mutations might occur, but there were no significant changes in the preexisting resistance patterns. Our data show that combination therapy consisting of CT and HAART is feasible and that the virological response can be maintained in the majority of patients receiving this treatment.

Original languageEnglish
Pages (from-to)820-827
Number of pages8
JournalClinical Infectious Diseases
Volume37
Issue number6
DOIs
Publication statusPublished - Sep 15 2003

Fingerprint

Viremia
Highly Active Antiretroviral Therapy
Non-Hodgkin's Lymphoma
HIV
Drug Therapy
Cyclophosphamide
Genotype
Phenotype
Vincristine
Etoposide
Prednisone
Doxorubicin
Therapeutics
Mutation

ASJC Scopus subject areas

  • Immunology

Cite this

Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma. / Simonelli, Cecilia; Zanussi, Stefania; Cinelli, Roberta; Dal Maso, Luigino; Di Gennaro, Giampiero; D'Andrea, Monica; Nasti, Guglielmo; Spina, Michele; Vaccher, Emanuela; De Paoli, Paolo; Tirelli, Umberto.

In: Clinical Infectious Diseases, Vol. 37, No. 6, 15.09.2003, p. 820-827.

Research output: Contribution to journalArticle

@article{d61278f63dc743d0bc960eefc60a27aa,
title = "Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma",
abstract = "We evaluated the replication and resistance patterns of human immunodeficiency virus (HIV) strains recovered from HIV-infected patients with non-Hodgkin lymphoma (NHL) who were receiving chemotherapy (CT) concomitant with highly active antiretroviral therapy (HAART). We analyzed virological response to HAART in 35 patients with HIV and NHL who were treated with a cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy regimen and HAART and the virological response in 26 HIV-infected patients with CD20 cell-positive NHL who were treated with rituximab and cyclophosphamide-doxorubin-etoposide therapy. Genotype and virtual phenotype analyses were performed at baseline and when virological failure occurred. Only 9 patients met the criteria for virological failure. Genotype and virtual phenotype analyses demonstrated that, during CT administration, new mutations might occur, but there were no significant changes in the preexisting resistance patterns. Our data show that combination therapy consisting of CT and HAART is feasible and that the virological response can be maintained in the majority of patients receiving this treatment.",
author = "Cecilia Simonelli and Stefania Zanussi and Roberta Cinelli and {Dal Maso}, Luigino and {Di Gennaro}, Giampiero and Monica D'Andrea and Guglielmo Nasti and Michele Spina and Emanuela Vaccher and {De Paoli}, Paolo and Umberto Tirelli",
year = "2003",
month = "9",
day = "15",
doi = "10.1086/377204",
language = "English",
volume = "37",
pages = "820--827",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma

AU - Simonelli, Cecilia

AU - Zanussi, Stefania

AU - Cinelli, Roberta

AU - Dal Maso, Luigino

AU - Di Gennaro, Giampiero

AU - D'Andrea, Monica

AU - Nasti, Guglielmo

AU - Spina, Michele

AU - Vaccher, Emanuela

AU - De Paoli, Paolo

AU - Tirelli, Umberto

PY - 2003/9/15

Y1 - 2003/9/15

N2 - We evaluated the replication and resistance patterns of human immunodeficiency virus (HIV) strains recovered from HIV-infected patients with non-Hodgkin lymphoma (NHL) who were receiving chemotherapy (CT) concomitant with highly active antiretroviral therapy (HAART). We analyzed virological response to HAART in 35 patients with HIV and NHL who were treated with a cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy regimen and HAART and the virological response in 26 HIV-infected patients with CD20 cell-positive NHL who were treated with rituximab and cyclophosphamide-doxorubin-etoposide therapy. Genotype and virtual phenotype analyses were performed at baseline and when virological failure occurred. Only 9 patients met the criteria for virological failure. Genotype and virtual phenotype analyses demonstrated that, during CT administration, new mutations might occur, but there were no significant changes in the preexisting resistance patterns. Our data show that combination therapy consisting of CT and HAART is feasible and that the virological response can be maintained in the majority of patients receiving this treatment.

AB - We evaluated the replication and resistance patterns of human immunodeficiency virus (HIV) strains recovered from HIV-infected patients with non-Hodgkin lymphoma (NHL) who were receiving chemotherapy (CT) concomitant with highly active antiretroviral therapy (HAART). We analyzed virological response to HAART in 35 patients with HIV and NHL who were treated with a cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy regimen and HAART and the virological response in 26 HIV-infected patients with CD20 cell-positive NHL who were treated with rituximab and cyclophosphamide-doxorubin-etoposide therapy. Genotype and virtual phenotype analyses were performed at baseline and when virological failure occurred. Only 9 patients met the criteria for virological failure. Genotype and virtual phenotype analyses demonstrated that, during CT administration, new mutations might occur, but there were no significant changes in the preexisting resistance patterns. Our data show that combination therapy consisting of CT and HAART is feasible and that the virological response can be maintained in the majority of patients receiving this treatment.

UR - http://www.scopus.com/inward/record.url?scp=0141453197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141453197&partnerID=8YFLogxK

U2 - 10.1086/377204

DO - 10.1086/377204

M3 - Article

VL - 37

SP - 820

EP - 827

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -